Methamphetamine use disorder is one of the most difficult substance addictions to treat, affecting an estimated large number of people globally — some estimates suggest tens of millions of users worldwide. With no FDA-approved medications for methamphetamine dependence and high relapse rates with behavioral therapies alone, researchers and clinicians are exploring novel approaches — including ibogaine, a psychoactive alkaloid derived from the Tabernanthe iboga plant. Interest in ibogaine for stimulant disorders is growing, though the evidence base remains in its earliest stages.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision required. Do not self-administer.

What the Research Shows

Honest framing matters here: there are currently no completed randomized controlled trials of ibogaine specifically for methamphetamine use disorder. The existing evidence comes from preclinical animal studies, a small number of case reports, open-label case series that included stimulant-dependent patients alongside opioid-dependent patients, and observational data from ibogaine clinics. This does not mean the research is unimportant — it means findings must be interpreted with appropriate caution.

Preclinical Evidence

The most consistent preclinical signal comes from rodent studies by pharmacologist Stanley Glick and colleagues, who investigated ibogaine and its synthetic analog 18-MC (18-methoxycoronaridine) across multiple addiction models. These studies found that ibogaine and 18-MC reduced self-administration of morphine, cocaine, nicotine, and — critically — methamphetamine in rodents. The 18-MC analog was developed specifically to retain ibogaine's anti-addictive properties while reducing cardiac and neurotoxic risk. In preclinical models, 18-MC reduced methamphetamine self-administration without producing the cerebellar neurotoxicity observed at high ibogaine doses in rodents.

These findings are biologically meaningful but carry the usual limitations of animal-to-human translation: rodent addiction models do not fully replicate the complexity of human stimulant use disorder, dosing in animals does not map cleanly to human equivalents, and no Phase II or Phase III human trial of ibogaine or 18-MC for methamphetamine has been completed.

Open-Label Clinical Observations

A large open-label case series by Mash DC et al. (2018), published in Frontiers in Pharmacology, examined outcomes in 191 patients treated with ibogaine at a clinic in St. Kitts. The study population included both opioid-dependent and cocaine-dependent patients — not methamphetamine specifically — but it demonstrated that ibogaine could be administered in a supervised clinical setting with measurable reductions in craving and withdrawal symptoms across stimulant-class substances. No serious adverse events were reported within the study's observation window. This study is frequently cited in discussions of ibogaine for stimulant disorders, though its open-label, uncontrolled design limits conclusions about efficacy.

Separately, the observational study by Brown TK & Alper K (2018), published in the American Journal of Drug and Alcohol Abuse, followed 30 opioid-dependent patients for 12 months after ibogaine treatment — this study was opioid-specific and should not be generalized to methamphetamine outcomes.

Case Reports and Clinic Data

Ibogaine providers in Mexico, the Netherlands, and South Africa — where ibogaine is legal or unregulated — have treated patients with methamphetamine use disorder and published case descriptions noting reductions in craving and periods of abstinence following treatment. These accounts are clinically interesting but are subject to significant selection bias, lack of controls, and inconsistent outcome measurement. They cannot establish efficacy.

What About GLYX-13 or Neuroinflammation Research?

Emerging neuroscience research on methamphetamine-associated neurotoxicity — including dopaminergic and serotonergic nerve terminal damage — has raised interest in whether ibogaine's proposed neuroplasticity-promoting effects (particularly via GDNF upregulation and sigma-2 receptor activity) could help repair stimulant-related brain changes. This hypothesis is scientifically plausible but has not been tested in human clinical trials for methamphetamine specifically.

Clinical Trial Results

The table below reflects the state of published clinical evidence. No completed, published RCT exists for ibogaine in methamphetamine use disorder specifically.

Study Design N Population Key Finding Year
Mash DC et al. Open-label case series 191 Opioid & cocaine dependence Reductions in craving and withdrawal; no serious adverse events reported in study window 2018
Glick SD et al. (multiple) Preclinical rodent studies N/A Rodent methamphetamine self-administration models 18-MC and ibogaine reduced meth self-administration; 18-MC showed reduced toxicity Various
No completed RCT — — Methamphetamine use disorder No Phase II or III human trial completed as of 2026 —

How Ibogaine May Help

While the clinical evidence is limited, several proposed mechanisms are relevant specifically to methamphetamine's profile of harm:

Dopamine System Modulation

Methamphetamine acts primarily by flooding the brain with dopamine — and chronic use downregulates dopamine receptors and depletes dopamine transporters. Ibogaine interacts with the dopamine system through multiple pathways, including dopamine transporter (DAT) binding and inhibition of dopamine reuptake. Whether these interactions can partially restore dopaminergic tone after methamphetamine-induced damage is an open research question, but the mechanistic overlap is scientifically noteworthy.

GDNF Upregulation

Preclinical studies have found that ibogaine increases expression of glial cell line-derived neurotrophic factor (GDNF), a protein that promotes the survival and repair of dopaminergic neurons. Because methamphetamine causes demonstrable damage to dopaminergic terminals in the striatum and prefrontal cortex, this GDNF-mediated neuroprotective or neurorestorative effect is of particular theoretical relevance — and a key reason ibogaine research in stimulant disorders is scientifically motivated.

Sigma-2 and NMDA Receptor Activity

Ibogaine and its metabolite noribogaine act at sigma-2 receptors and NMDA receptors, which are implicated in memory reconsolidation, craving, and the neuroplastic changes underlying addiction. These receptor interactions may help "interrupt" the deeply conditioned associations between methamphetamine cues and drug-seeking behavior — though this mechanism remains incompletely understood.

Serotonergic Effects

Methamphetamine also damages serotonergic neurons. Ibogaine has significant activity at serotonin transporters (SERT), and its metabolite noribogaine is a potent serotonin reuptake inhibitor. Whether serotonergic modulation contributes to anti-addictive effects in stimulant users is not established, but it represents another plausible mechanism.

Psychological Reset and Therapeutic Context

Unlike opioid withdrawal, methamphetamine withdrawal does not involve severe physical dependence — but the psychological craving, anhedonia, and cognitive impairment that follow cessation are intense and prolonged. Ibogaine's long (36–72 hour) psychedelic experience may facilitate psychological insight and motivation for change in ways that complement or exceed what behavioral therapy alone can achieve. This is speculative in the context of methamphetamine but consistent with the broader psychedelic-assisted therapy literature.

Limitations and What We Don't Know Yet

  • No completed RCT: The absence of a randomized, placebo-controlled trial for methamphetamine use disorder means efficacy cannot be established. Open-label and case series data are hypothesis-generating, not confirmatory.
  • Stimulant vs. opioid distinction matters: Most of the positive ibogaine clinical data comes from opioid-dependent populations. Methamphetamine and opioids involve different neurobiological mechanisms; findings do not translate automatically.
  • Optimal dosing unknown: No established safe or effective dose for methamphetamine use disorder has been defined in humans.
  • Duration of effect unclear: Even in opioid studies, ibogaine's effects on abstinence tend to diminish over time. Whether any single treatment produces durable change in methamphetamine users — and whether repeat dosing is safe — is unknown.
  • Neurotoxicity in stimulant users: Methamphetamine itself causes brain changes that may affect how ibogaine is metabolized or tolerated. Drug-drug interactions between residual methamphetamine and ibogaine could be dangerous.
  • 18-MC analog status: The 18-MC analog, which showed the most promising preclinical signal for methamphetamine, has not progressed to a completed human efficacy trial as of 2026.
  • Publication bias: Positive case reports from clinics are more likely to be published or publicized than neutral or negative outcomes.

Safety Considerations

Ibogaine's safety profile presents specific concerns for people with methamphetamine use disorder:

Cardiac Risk

Ibogaine prolongs the cardiac QTc interval, which can cause potentially fatal arrhythmias. Methamphetamine itself causes cardiovascular damage — including cardiomyopathy, coronary artery disease, and arrhythmias — that may substantially increase cardiac risk when combined with ibogaine's QTc effects. A thorough cardiac workup (ECG, echocardiogram) is essential before any ibogaine administration in methamphetamine users, and treatment should be conducted with cardiac monitoring and magnesium co-administration under medical supervision.

Drug-Drug Interactions

Methamphetamine and ibogaine are both metabolized through CYP2D6 and CYP3A4 pathways. Concurrent or recent methamphetamine use could significantly affect ibogaine metabolism and toxicity. A mandatory drug-free clearance period is standard practice in supervised settings.

Seizure Risk

Both methamphetamine and ibogaine lower the seizure threshold through different mechanisms. Individuals with methamphetamine-associated brain changes may have elevated baseline seizure risk during ibogaine treatment.

Psychiatric Considerations

Methamphetamine use disorder is frequently associated with methamphetamine-induced psychosis, which may persist weeks or months after cessation. Ibogaine's intense psychedelic effects could exacerbate psychotic symptoms or trigger relapse to psychosis. A thorough psychiatric evaluation is essential before treatment.

Fatality Risk

Ibogaine-related deaths have been reported worldwide, most often attributable to cardiac events, polydrug interactions, and inadequate screening. People with methamphetamine-associated cardiovascular damage are at elevated risk. Treatment should only occur in medically supervised settings with emergency equipment available.

Current Treatment Landscape

Methamphetamine use disorder is notable — and frustrating — for its lack of FDA-approved pharmacotherapies. Unlike opioid use disorder (buprenorphine, methadone, naltrexone) or alcohol use disorder (naltrexone, acamprosate, disulfiram), there is currently no approved medication for methamphetamine dependence. This treatment gap is one reason ibogaine and other novel approaches attract scientific and patient interest.

Current standard-of-care approaches include:

  • Contingency management (CM): The most evidence-backed behavioral intervention; uses tangible incentives to reinforce abstinence. Effective but requires sustained clinical infrastructure and patient engagement.
  • Cognitive-behavioral therapy (CBT): Widely used to address triggers, craving, and relapse. Effective for some patients; high dropout rates.
  • Matrix Model: A structured 16-week outpatient program combining CBT, family education, and support groups, developed specifically for stimulant use disorders.
  • Off-label pharmacotherapies: Medications including naltrexone, bupropion, and mirtazapine have been studied with mixed results; none are approved for this indication.
  • Bupropion + naltrexone combination: Some trial data has suggested modest but potentially meaningful benefit for heavy methamphetamine users — among the more promising pharmacological results to date, though not yet standard of care.

Within this landscape, ibogaine sits firmly in the experimental category — potentially filling a role that no approved treatment currently occupies, particularly for patients who have failed behavioral and pharmacological approaches. Research is needed to determine whether that potential translates to real-world benefit.

Frequently Asked Questions

No — not by the standard of a randomized controlled trial. There is preclinical evidence from animal studies showing that ibogaine and its analog 18-MC reduce methamphetamine self-administration in rodents, and open-label case series data from clinics treating mixed stimulant populations. However, no completed Phase II or III human trial has tested ibogaine specifically for methamphetamine use disorder. The evidence is promising enough to justify further research, but it cannot currently support a claim that ibogaine is a proven treatment for methamphetamine addiction.
The distinction is important. Most of ibogaine's clinical evidence — including its well-documented ability to interrupt opioid withdrawal — comes from opioid-dependent populations. Methamphetamine does not produce the same type of physical withdrawal; its main challenge is intense psychological craving, anhedonia, and prolonged dopamine dysregulation. Ibogaine's proposed mechanisms for methamphetamine are different (dopamine system modulation, GDNF upregulation) and less well-tested in humans. Do not assume that evidence from opioid studies automatically applies to methamphetamine.
Potentially yes. Chronic methamphetamine use causes cardiovascular damage — including cardiomyopathy and increased arrhythmia risk — that may compound ibogaine's cardiac QTc prolongation. Both substances also lower the seizure threshold and interact with overlapping metabolic pathways. Methamphetamine-associated psychosis is another concern, as ibogaine's intense psychedelic effects could be destabilizing in someone with a history of stimulant-induced psychiatric episodes. Thorough cardiac and psychiatric screening is particularly important for this population.
18-MC (18-methoxycoronaridine) is a synthetic analog of ibogaine developed by pharmacologist Stanley Glick and colleagues. It was designed to preserve ibogaine's anti-addictive properties while reducing its hallucinogenic effects and potential for cardiac and cerebellar toxicity. In preclinical rodent models, 18-MC reduced self-administration of methamphetamine, among other drugs. It has attracted research interest as a potentially safer ibogaine-derived compound for stimulant use disorders. However, as of 2026, 18-MC has not completed a human efficacy trial specifically for methamphetamine use disorder, so it remains experimental.
Ibogaine is a Schedule I controlled substance in the United States, meaning it cannot be prescribed or administered legally outside of an approved research protocol. Supervised ibogaine clinics operate legally in Mexico, the Netherlands, and several other countries. Anyone considering treatment should be aware that: (1) evidence specifically for methamphetamine is limited; (2) the quality of screening and medical supervision varies significantly between clinics; (3) cardiac and psychiatric evaluation before treatment is essential; and (4) ibogaine-related deaths have occurred in under-supervised settings. Participating in a clinical trial, where one exists, provides the safest and most evidence-generating path.
Clinical trials are the safest way to access experimental treatments and contribute to the evidence base. As of 2026, dedicated trials for ibogaine in methamphetamine use disorder are limited. Checking ClinicalTrials.gov for active studies under terms like "ibogaine stimulant" or "18-MC methamphetamine" may identify current opportunities. Academic medical centers with psychedelic research programs — including those affiliated with MAPS or HBRI (Multidisciplinary Association for Psychedelic Studies / Healing Breakthrough Research Institute) — are worth contacting directly. A physician or addiction specialist can help evaluate eligibility and safety.
Several factors have slowed clinical research. Ibogaine's Schedule I status in the US creates significant regulatory barriers to human trials. Its cardiac safety profile requires expensive monitoring infrastructure. Pharmaceutical companies have little financial incentive to develop a non-patentable plant compound. And most ibogaine research funding has historically focused on opioid use disorder, where the withdrawal-interrupting effect is most dramatic and easiest to measure. Growing awareness of the methamphetamine treatment gap — and the total absence of FDA-approved pharmacotherapies — is beginning to attract more targeted research interest.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.